S1 Ep211: Exploring and Managing Gastrointestinal-Related CAR T-Cell Lymphomas

About this episode

The episode discusses a study on CAR T-cell-related lymphomas in the gastrointestinal tract, focusing on a patient case involving relapsed/refractory multiple myeloma.

In a special cobranded episode between Oncology On the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks , host Rahul Banerjee, MD, FACP, spoke with colleague Hitomi Hosoya, MD, PhD, about a study she and coauthors published in Blood. In their study, Hosoya and colleagues assessed the underlying mechanisms of CAR T-cell–related lymphomas developing in the gastrointestinal tract. The study focused on a particular case involving a 50-year-old patient with relapsed/refractory multiple myeloma who developed T-cell lymphoma after receiving cellular therapy in the seventh-line setting. The discussion began with an overview of the patient’s treatment course, who initially responded well to seventh-line CAR T-cell therapy and experienced grade 1 cytokine release syndrome with no neurotoxicity. Two months after initiating this line of therapy, the patient experienced diarrhea and subsequent hospitalization. Following multiple endoscopies and the use of steroids and other biologic agents, the patient’s diarrhea persisted, which resulted in notable weight loss and cachexia. A biopsy revealed that the patient had…

People in this episode

Host: Rahul Banerjee, MD, FACP

Guest: Hitomi Hosoya, MD, PhD

Topics covered

• CAR T-cell therapy
• gastrointestinal lymphomas
• multiple myeloma
• patient case study
• symptom management

Keywords

• CAR T-cell therapy
• gastrointestinal lymphomas
• multiple myeloma
• cytokine release syndrome
• T-cell lymphoma
• patient case
• symptom management

Mentioned in this episode

Organizations: American Society for Transplantation and Cellular Therapy, CancerNetwork

Books & works: Blood

More episodes of Oncology On The Go

• S1 Ep218: Unraveling Key Hematologic Oncology Developments at ASCO 2026 · June 8, 2026 · 24 min
• S1 Ep217: Integrating Exercise and Lifestyle Intervention Into Oncologic Therapy · June 1, 2026 · 29 min
• S1 Ep216: How the Landscape of GI Oncology is Evolving | A 2026 ASCO Preview · May 28, 2026 · 29 min
• S1 Ep215: Navigating The Dynamic Landscape of Stem Cell Transplantation · May 25, 2026 · 11 min
• S1 Ep214: Are Zedoresertib and Lunresertib an Efficacious Combo Across Solid Tumors? · May 18, 2026 · 13 min
• S1 Ep213: What Does the Future Hold for Immune Effector Cell Therapies? · May 11, 2026 · 12 min